Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan + dose-reduced amoxicillin dual therapy vs standard quadruple therapy for first-line H. pylori eradication
ChiCTR2500096827Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of vonoprazan and amoxicillin in Helicobacter pylori infection and chronic gastritis (3 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: eradication rate and incidence of adverse reactions. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
vonoprazanamoxicillin
03
Conditions
Helicobacter pylori infectionchronic gastritis
Beyond the preview
Go deeper on ChiCTR2500096827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096827.